Cost effectiveness of Interferon α2b combined with ribavirin for the treatment of chronic hepatitis C

Hepatology

Volumn 30, Issue 5, 1999, Pages 1318-1324

  Younossi, Zobair M ^a   Singer, Mendel E ^b   Mchutchison, John G ^c   Shermock, Kenneth M ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ARTICLE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEPATITIS C; HUMAN; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; TREATMENT OUTCOME; TREATMENT PLANNING; VIRUS GENE;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION TREES; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; PROBABILITY; QUALITY OF LIFE; RIBAVIRIN; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 0032731788     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300518     Document Type: Article

References (13)

1. Alter HJ. To C or not to C: these are the questions. Blood 1995;85:1681-1695.
2. Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993;88:240-243.
3. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, et al. The long-term pathological evolution of chronic hepatitis C. HEPATOLOGY 1996;23:1334-1340.
4. Fattovich G, Guistina G, Degas E Morbidity and mortality in compenstated cirrhosis type C: a retrospective follow up study of 384 patients. Gastroenterology 1997;112:463-472.
5. Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, Nakanishi K, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797-1801.
6. Colombo M, de Franchis R, Del Ninno E, Sangiovanni A, De Fazio C, Tommasini M, Donato MF, et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 1991;325:675-680.
7. Ascher ML, Lake JR, Emond J, Roberts J. Liver transplantation for hepatitis C virus-related cirrhosis. HEPATOLOGY 1994;20:24S-27S.
8. Detre KM, Belle SH, Lomarddero M. Liver transplantation for chronic viral hepatitis. Viral Hepatitis Rev 1996;2:219-228.
9. Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-561.
10. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer H, Perillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-1506.
11. Davis GL, Lau JYN, Lim HL. Therapy for chronic hepatitis C. Gastroenterol Clin North Am 1994:23:603-613.
12. Fried MW, Hoofnagle JH. Therapy of Hepatitis C. Semin Liver Dis 1995:15:82-91.
13. Chemello L, Cavalletto L, Noventa F, Bonetti P, Casarin C, Bernardinello E, Pontisso P, et al. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-a. J Viral Hepat 1995;2:91-96.